Hyperresponsiveness of platelets in ischemic stroke.

Abstract:

:Platelet activation and aggregation are critical in the pathogenesis of acute ischemic cerebrovascular diseases. The aim of our study was to characterize platelet function in patients with acute ischemic stroke or transient ischemic attack (TIA), and to evaluate the effect of platelet activation on clinical outcome. One hundred thirty-eight consecutive patients with TIA (n = 74) or stroke (n = 64) were enrolled in this study. Platelet aggregation in response to ADP, epinephrine, arachidonic acid, or collagen, and expression of platelet activation receptors (CD62P, CD63, LIBS-1 and PAC-1) in the acute phase and at three months follow-up were evaluated. Platelets derived from stroke patients were more hyperaggregable in response to agonists in the acute phase compared to TIA patients (p[ADP] = 0.002, p[arachidonic acid] = 0.047, p[epinephrine] = 0.020). Platelet activation was enhanced in the acute phase irrespective of the severity of the disease (stroke or TIA) and returned to baseline levels three months later. Persistent elevated platelet activation at three months follow-up (PAC-1) was associated with increased incidence of recurrent stroke (median, [interquartile range] 3.4, [3.0-5.2] versus 2.9, [2.3-4.0], p = 0.048). In conclusion, platelets are hyperactive in acute stroke compared with TIA. A more intensified dual antiplatelet therapy may be of benefit for stroke patients.

journal_name

Thromb Haemost

authors

Fateh-Moghadam S,Htun P,Tomandl B,Sander D,Stellos K,Geisler T,Langer H,Walton K,Handschu R,Garlichs C,Daniel WG,Gawaz M

subject

Has Abstract

pub_date

2007-06-01 00:00:00

pages

974-8

issue

6

eissn

0340-6245

issn

2567-689X

pii

07060974

journal_volume

97

pub_type

杂志文章
  • Factor VIIa in patients with C1-inhibitor deficiency.

    abstract::In hereditary angioedema (HAE), normal C1-inhibitor (C1-INH) is low and the contact system activated. Recently, the findings of a tissue factor mutant selectively deficient in promoting the conversion of FVII to FVIIa, but with retained cofactor for FVIIa, made it possible to examine reliably the pre-existing content ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Nielsen EW,Morrissey J,Olsen JO,Osterud B

    更新日期:1995-10-01 00:00:00

  • Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results.

    abstract::LMWH preparations have been proven to be safe and effective in the out-patient management of acute DVT. Although LMWHs are more expensive than unfractionated heparin, the lack of need for laboratory monitoring of LMWHs and their potential for out-patient treatment more than offsets the drug related cost difference and...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章,评审

    doi:

    authors: Hirsh J,Crowther M

    更新日期:1997-07-01 00:00:00

  • Venous antithrombotic and anticoagulant activities of a fucoïdan fraction.

    abstract::Fucoïdans catalyse thrombin inhibition by antithrombin (AT) and heparin cofactor II (HCII); their affinity for each serpin varies according to the seaweed species from which they are extracted, as well as their chemical composition and molecular weight. We extracted a homogeneous fucoïdan fraction from Ascophyllum nod...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Mauray S,Sternberg C,Theveniaux J,Millet J,Sinquin C,Tapon-Bretaudière J,Fischer AM

    更新日期:1995-11-01 00:00:00

  • Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation.

    abstract::The efficacy of conventional dose adjusted oral anticoagulation for stroke prevention in patients with non-valvular atrial fibrillation is well-documented but not considered ideal as primary antithrombotic treatment in elderly patients. The antithrombotic effect of fixed minidose warfarin 1.25 mg/day alone or in combi...

    journal_title:Thrombosis and haemostasis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Koefoed BG,Feddersen C,Gulløv AL,Petersen P

    更新日期:1997-05-01 00:00:00

  • Characterisation of a monoclonal antibody to von Willebrand factor as a potent inhibitor of ristocetin-mediated platelet interaction and platelet adhesion.

    abstract::We studied a murine monoclonal antibody (211 A6) to von Willebrand factor (vWF) with a view to investigating structure-relationship of plasma vWF. The specificity of this antibody has been substantiated by ELISA tests and indirect immunofluorescence. It reacts with purified vWF, normal plasma but not with plasma or pl...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Jorieux S,de Romeuf C,Samor B,Goudemand M,Mazurier C

    更新日期:1987-06-03 00:00:00

  • Antithrombin III and heparin inactivation in thrombin involving reactions.

    abstract::The inhibitory capacity of antithrombin III (AT III) was measured by a quantitative method independent of the velocity of inhibition. When AT III was in excess of thrombin in plasma or in purified system the capacity of inhibitor decreased quantitatively in proportion to the amount of thrombin neutralized. Heparin pre...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Marciniak E

    更新日期:1977-08-31 00:00:00

  • Evaluation of the effect of betapropiolactone/ultraviolet irradiation (BPL/UV) treatment of source plasma on hepatitis transmission by factor IX complex in chimpanzees.

    abstract::To evaluate the safety of a beta-Propiolactone/Ultraviolet (BPL/UV), irradiated Factor IX complex preparation we inoculated 8 chimpanzees with 25 units Factor IX/Kilo from a pool of 5 production lots which had been treated in this manner. These lots were derived from approximately 1,000 donors. Animals were followed w...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Prince AM,Stephan W,Brotman B,van den Ende MC

    更新日期:1980-12-19 00:00:00

  • Extrinsic pathway inhibitor in elective surgery: a comparison with other coagulation inhibitors.

    abstract::Extrinsic coagulation pathway inhibitor may be an important regulator of haemostasis to prevent thrombosis after tissue damage. The functional activity of this inhibitor was determined using a chromogenic substrate assay, and compared to the activities of antithrombin, heparin cofactor II and protein C during the peri...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Sandset PM,Høgevold HE,Lyberg T,Andersson TR,Abildgaard U

    更新日期:1989-11-24 00:00:00

  • The lysosomal granule membrane protein, LAMP-2, is also present in platelet dense granule membranes.

    abstract::Lysosomal Associated Membrane Protein-2 (LAMP-2) is an inherent component of lysosomal granule membranes in diverse cell types, including platelets. We examined platelets for evidence of LAMP-2 in dense granule membranes as CD63 has previously been shown to be present in both lysosomal and dense granule membranes. Imm...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Israels SJ,McMillan EM,Robertson C,Singhory S,McNicol A

    更新日期:1996-04-01 00:00:00

  • Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens.

    abstract::Emicizumab, a humanised bispecific antibody recognising factors (F) IX/IXa and X/Xa, can accelerate FIXa-catalysed FX activation by bridging FIXa and FX in a manner similar to FVIIIa. However, details of the emicizumab-antigen interactions have not been reported so far. In this study, we first showed by surface plasmo...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH17-01-0030

    authors: Kitazawa T,Esaki K,Tachibana T,Ishii S,Soeda T,Muto A,Kawabe Y,Igawa T,Tsunoda H,Nogami K,Shima M,Hattori K

    更新日期:2017-06-28 00:00:00

  • Effect of carbohydrate modifications of factor VIII/von Willebrand factor on binding to platelets.

    abstract::This study compares the ability of unmodified and carbohydrate-modified forms of factor VIII/von Willebrand factor (FVIII/vWF) protein to bind to platelets in the presence of ristocetin or thrombin. Treatment of intact FVIII/vWF with alpha-D-neuraminidase results in more than 95% desialylation. Asialo FVIII/vWF retain...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Goudemand J,Mazurier C,Samor B,Bouquelet S,Montreuil J,Goudemand M

    更新日期:1985-06-24 00:00:00

  • Collagen induced thrombus formation at the apex of eccentric stenoses--a time course study with non-anticoagulated human blood.

    abstract::Atherosclerotic plaque rupture may trigger the formation of mural thrombus. This thrombus formation is apparently affected by very high and complex shear conditions introduced by the luminal narrowing (stenosis) of the atheroma. To study the impact of such blood flow behaviour on thrombus formation we employed a model...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Barstad RM,Kierulf P,Sakariassen KS

    更新日期:1996-04-01 00:00:00

  • Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty.

    abstract::It was the objective of this study to determine whether reduced cleavage of von Willebrand factor (VWF) multimers following aortic valve replacement (AVR) is a consequence of reduced shear stress or postoperative changes in VWF cleavage protease (ADAMTS-13) activity. Aortic stenosis (AS) may be complicated by acquired...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH11-12-0803

    authors: Bander J,Elmariah S,Aledort LM,Dlott J,Stelzer P,Halperin JL,Kini AS,Sharma SK

    更新日期:2012-07-01 00:00:00

  • Lysophosphatidylcholine decreases the synthesis of tissue factor pathway inhibitor in human umbilical vein endothelial cells.

    abstract::Thrombotic complications are frequently associated with atherosclerosis. Lysophosphatidylcholine (LPC), a component accumulated in oxidatively modified LDL (ox-LDL), is known to play a crucial role in the initiation and progression of atherosclerotic vascular lesions. Since a vascular anticoagulant, tissue factor path...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Sato N,Kokame K,Miyata T,Kato H

    更新日期:1998-01-01 00:00:00

  • Nuclear factor-κB regulates expression of platelet phospholipase C-β2 (PLCB2).

    abstract::Phospholipase C (PLC)-β2 (gene PLCB2) is a critical regulator of platelet responses upon activation. Mechanisms regulating of PLC-β2 expression in platelets/MKs are unknown. Our studies in a patient with platelet PLC-β2 deficiency revealed the PLCB2 coding sequence to be normal and decreased platelet PLC-β2 mRNA, sugg...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH15-09-0749

    authors: Mao G,Jin J,Kunapuli SP,Rao AK

    更新日期:2016-10-28 00:00:00

  • Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation.

    abstract::The mechanism underlying a hyperreactive platelet phenotype remains unknown. Since serotonin has been shown to influence platelet biology and atherothrombosis, we sought to investigate the association of platelet serotonin transporter number, binding affinity, and uptake kinetics with platelet aggregation. A total of ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH12-03-0202

    authors: Berger JS,Becker RC,Kuhn C,Helms MJ,Ortel TL,Williams R

    更新日期:2013-01-01 00:00:00

  • In proven deep vein thrombosis, a low positive D-Dimer score is a strong negative predictor for associated malignancy.

    abstract::D-Dimer measurements are being increasingly used for negative prediction of deep vein thrombosis (DVT). At our institution, clinical score, D-Dimer assay, plethysmography and, if necessary, Doppler ultrasound are used to secure the diagnosis. We collected the data from 100 consecutive patients proven to have DVT. We e...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH03-11-0699

    authors: Rege KP,Jones S,Day J,Hoggarth CE

    更新日期:2004-06-01 00:00:00

  • Antithrombotic activity of LB30057, a newly synthesized direct thrombin inhibitor.

    abstract::An amidrazonophenylalanine derivative, LB30057, inhibits the catalytic activity of thrombin potently by interaction with the active site of thrombin, and has high water solubility. In the present study, we evaluated the effect of LB30057 on the biological activities of thrombin at various tissues, and determined wheth...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Kang KT,Jung BI,Bae ON,Lee MY,Chung SM,Lee JY,Lee SK,Kim IC,Chung JH

    更新日期:2003-01-01 00:00:00

  • Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis.

    abstract::Platelet adhesion and aggregation at the sites of vascular injury are key events for thrombosis and haemostasis. It has been well demonstrated that interaction between glycoprotein (GP) Ibα and von Willebrand factor (VWF) initiates platelet adhesion and contributes to platelet aggregation, particularly at high shear. ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH13-06-0490

    authors: Lei X,Reheman A,Hou Y,Zhou H,Wang Y,Marshall AH,Liang C,Dai X,Li BX,Vanhoorelbeke K,Ni H

    更新日期:2014-02-01 00:00:00

  • Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis.

    abstract::Clots formed from platelet rich plasma were found to be lysed more readily by low concentrations of pro-urokinase (pro-UK) than clots formed from platelet poor plasma. This was not a non-specific effect since the reverse occurred with tissue plasminogen activator. A mechanical explanation due to platelet-mediated clot...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Loza JP,Gurewich V,Johnstone M,Pannell R

    更新日期:1994-03-01 00:00:00

  • Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. DOS (Dermatan sulphate in Oncologic Surgery) Study Group.

    abstract:BACKGROUND:Patients undergoing surgery for cancer are at high risk for venous thromboembolism (VTE). Agents that selectively inhibit thrombin, such as dermatan sulphate, have potential for a favourable benefit-risk ratio in the prevention of this complication. METHODS:Patients scheduled for elective abdominal, thoraci...

    journal_title:Thrombosis and haemostasis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Di Carlo V,Agnelli G,Prandoni P,Coccheri S,Gensini GF,Gianese F,Mannucci PM

    更新日期:1999-07-01 00:00:00

  • Newborn platelet dysfunction: a storage pool and release defect.

    abstract::Per cent aggregation, release and content of adenine nucleotides, and specific radioactivity were evaluated in citrated platelet-rich plasma (PRP) prepared from paired samples of maternal and cord blood. Platelets of newborn infants aggregated normally in response to highdose ADP (20 muM), strong collagen suspensions,...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Corby DG,Zuck TF

    更新日期:1976-08-31 00:00:00

  • Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era.

    abstract::Antithrombin (AT) activity tests are used for diagnosing hereditary AT deficiency, a main genetic determinant of thrombophilia. They are either based on inhibition of thrombin (FIIa) or activated factor X (FXa). FXa-based assays have been suggested to be preferable to FIIa-based assays due to their higher sensitivity ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH17-08-0568

    authors: Rühl H,Reda S,Müller J,Oldenburg J,Pötzsch B

    更新日期:2018-02-01 00:00:00

  • Recombinant factor VIIa does not induce hypercoagulability in vitro.

    abstract::Recombinant factor VIIa (rVIIa) has been reported to be clinically effective and safe in haemophilic patients with inhibitor antibodies. Compared to activated prothrombin complex concentrates the risk of thrombotic complications seems to be very low after rVIIa administration. Determination of free thrombin generation...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Gallistl S,Cvirn G,Muntean W

    更新日期:1999-02-01 00:00:00

  • Expression of vascular endothelial growth factor in human monocyte/macrophages stimulated with lipopolysaccharide.

    abstract::Vascular endothelial growth factor (VEGF) is a mitogen for endothelial cells. We have studied the production of VEGF by human macrophages in response to lipopolysaccharide (LPS). Macrophages stimulated with LPS expressed VEGF mRNA and protein in concentration- and time-dependent manners. The LPS-induced expression of ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Itaya H,Imaizumi T,Yoshida H,Koyama M,Suzuki S,Satoh K

    更新日期:2001-01-01 00:00:00

  • Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator.

    abstract::The influence of changes in liver blood flow on the clearance of rt-PA was studied both in healthy subjects and in a perfused rat liver model. Liver blood flow in healthy subjects was documented indirectly by the clearance of indocyanine green (ICG). Exercise reduced liver blood flow on average by 57% with a 95% confi...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: de Boer A,Kluft C,Kroon JM,Kasper FJ,Schoemaker HC,Pruis J,Breimer DD,Soons PA,Emeis JJ,Cohen AF

    更新日期:1992-01-23 00:00:00

  • Involvement of IRAKs and TRAFs in anti-β₂GPI/β₂GPI-induced tissue factor expression in THP-1 cells.

    abstract::Our previous study has shown that Toll-like receptor 4 (TLR4) and its signalling pathway contribute to anti-β₂-glycoprotein I/β₂-glycoprotein I (anti-β₂GPI/β₂GPI)-induced tissue factor (TF) expression in human acute monocytic leukaemia cell line THP-1 and annexin A2 (ANX2) is involved in this pathway. However, its dow...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH11-04-0229

    authors: Xu G,Wen H,Zhou H,Guo D,Zhou F,Chen D,Xie H,Wang T,Wang H

    更新日期:2011-12-01 00:00:00

  • Influence of the 4600A/G and 4678G/C polymorphisms in the endothelial protein C receptor (EPCR) gene on the risk of venous thromboembolism in carriers of factor V Leiden.

    abstract::Two polymorphisms in the endothelial protein C receptor (EPCR) gene, 4600A/G and 4678G/C, have been reported to influence the risk of venous thromboembolism (VTE). The objective of this study was to assess whether these polymorphisms modify the risk of VTE in carriers of factor V (FV) Leiden. We genotyped 295 carriers...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH05-02-0089

    authors: Medina P,Navarro S,Estellés A,Vayá A,Bertina RM,España F

    更新日期:2005-08-01 00:00:00

  • ADP-mimicking platelet aggregation caused by rugosin E, an ellagitannin isolated from Rosa rugosa Thunb.

    abstract::Among the nine ellagitannins, rugosin E was the most potent platelet aggregating agent with an EC50 of 1.5 +/- 0.1 microM in rabbit platelets and 3.2 +/- 0.1 microM in human platelets. The aggregations caused by rugosin E and ADP were inhibited by EGTA, PGE1, mepacrine, sodium nitroprusside and neomycin, but not by in...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Teng CM,Kang YF,Chang YL,Ko FN,Yang SC,Hsu FL

    更新日期:1997-03-01 00:00:00

  • Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.

    abstract::Edoxaban is an oral direct factor (F)Xa inhibitor in advanced stages of clinical development. The primary objective of the present study was to assess the pharmacodynamics (PD) and safety of enoxaparin 1 mg/kg followed 12 hours (h) post-dose by edoxaban 60 mg, which is the regimen being used in the phase III study of ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章,随机对照试验

    doi:10.1160/TH11-09-0676

    authors: Zahir H,Matsushima N,Halim AB,He L,Zhang G,Lee F,Worland V,Mendell J

    更新日期:2012-07-01 00:00:00